

CITATION REPORT

List of articles citing

**Clinical equivalence with G-CSF biosimilars:
methodologic approach in a (neo)adjuvant setting in
non-metastatic breast cancer**

DOI: 10.1007/s00520-017-3861-y
Supportive Care in Cancer, 2018, 26, 33-40.

Source: <https://exaly.com/paper-pdf/69627286/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2790-2801	3.8	16
3	Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies. <i>Future Oncology</i> , 2019 , 15, 1313-1322	3.6	6
2	Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era. <i>Frontiers in Oncology</i> , 2021 , 11, 697908	5.3	3
1	Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. <i>Annals of Translational Medicine</i> , 2019 , 7, 482	3.2	7